The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works. The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore.With Medicare the government directly funds pharmaceuticals for 65+ years old population.With Medicaid the government fund low income and other vulnerable populations.Given, that the private insurance sector will follow the lead of government negotiated prices, all prices will decrease.Revenues in the US will decline, and it will be interesting to see, what that will mean economically and in terms of availability of pharmaceuticals for the US and the global market? Please enjoy the discussion of market access veterans Dr. Stefan Walzer and Anita Burell MBA on this major change in the major market for pharmaceuticals. #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations#pricing #drugs #medtech #usa #inflationreductionact #inflation #ira

The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works. The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore. With Medicare the government directly funds pharmaceuticals for 65+ years old population. With Medicaid the government fund low income and other vulnerable populations. Given, that the private insurance sector will follow the lead of government negotiated prices, all prices will decrease. Revenues in the US will decline, and it will be interesting to see, what that will mean economically and in terms of availability of pharmaceuticals for the US and the global market? Please enjoy the discussion of market access veterans Dr. Stefan Walzer and Anita Burell MBA on this major change in the major market for pharmaceuticals. #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #drugs #medtech #usa #inflationreductionact #inflation #ira

The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works.&nbsp;The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore.With Medicare the government directly funds pharmaceuticals for 65+ years old population.With Medicaid the government fund low income and other vulnerable populations.Given, that the private insurance sector will follow the lead of government negotiated prices, all prices will decrease.Revenues in the US will decline, and it will be interesting to see, what that will mean economically and in terms of availability of pharmaceuticals for the US and the global market? Please enjoy the discussion of market access veterans Dr. Stefan Walzer and Anita Burell MBA on this major change in the major market for pharmaceuticals. #podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations#pricing #drugs #medtech #usa #inflationreductionact #inflation #ira

How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.
 
MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.
 
The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.
Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).
Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.

Business

Science

Medicine

Health & Fitness

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world.
 
MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access &amp; Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries.
 
The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access &amp; Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves.
Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany).
Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.

Share How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?

Sign up to save your podcasts

How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?

How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?

More shows like MAP - Market Access Podcast

Lage der Nation - der Politik-Podcast aus Berlin

The Prof G Pod with Scott Galloway

All-In with Chamath, Jason, Sacks & Friedberg

ASMR by GentleWhispering

The Memo by Howard Marks

LANZ & PRECHT

Prof G Markets

Market Access Matters